COVID Vaccine Developer/Manufacturer Announcements

 

COVID Vaccine Developer/Manufacturer Announcements
[relevant press releases/announcement from organizations from WHO EUL/PQ listing above]

 

AstraZeneca
Press Releases – No new digest announcements identified

Bharat Biotech – [Website not responding at inquiry]
Press Releases

BioCubaFarma – Cuba
Últimas Noticias – [Website not responding at inquiry; receiving 403-Forbidden]

 

CanSinoBIO
News – [Website not responding at inquiry]

Clover Biopharmaceuticals – China
News [Website not responding at inquiry]

 

Curevac [Bayer Ag – Germany]
News – No new digest announcements identified

 

Gamaleya National Center
Latest News and Events – No new digest announcements identified [See Russia/RFID below]

IMBCAMS, China
Home – No new digest announcements identified

 

Janssen/JNJ
Press Releases
Nov 10, 2021 United States
Johnson & Johnson Enters into Agreement to Provide its Single-Shot COVID-19 Vaccine for the World’s Most Vulnerable People through Novel Humanitarian Buffer
:: COVAX Humanitarian Buffer ensures the world’s most vulnerable people have access to COVID-19 vaccines
:: Approximately 167 million displaced people worldwide are at risk of exclusion from COVID-19 vaccination[1]
NEW BRUNSWICK, NJ (November 10, 2021) – Johnson & Johnson (NYSE: JNJ) (the Company) has entered into an agreement with the U.S. Government and Gavi, the Vaccine Alliance (Gavi), to enable access to its single-shot COVID-19 vaccine through a novel mechanism – the COVAX Humanitarian Buffer – that will serve to protect the world’s most vulnerable people. The first deliveries to the COVAX Humanitarian Buffer are anticipated to begin in the coming days…

 

Moderna
Press Releases
November 9, 2021
Moderna Files to Expand the Conditional Marketing Authorization for its COVID-19 Vaccine in the European Union to Include Children Ages 6-11 Years
Submission based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11

 

Novavax
Press Releases
Novavax Statement on UK and Mexico Phase 3 Clinical Trial Participants Considered Fully Vaccinated in the US Nov 10, 2021
The US Centers for Disease Control and Prevention (CDC) provided updated guidance (Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States) stating that Novavax clinical trial participants from sites outside the US are considered fully vaccinated if they received the same product that was administered and independently evaluated in the US clinical trials. This means that participants in the UK and Mexico Phase 3 clinical trials are considered fully vaccinated if they received the full series of active Novavax COVID-19 vaccine…

 

Pfizer
Recent Press Releases
11.11.2021
Zipline, Pfizer and BioNTech Collaboration Paves the Way for Automated, On-Demand Delivery of First mRNA COVID-19 Vaccines in Ghana
Zipline successfully completes world’s first long-range drone delivery of vaccines requiring ultra-cold-chain
…The collaboration of the companies, which worked together earlier this year to develop and test an end-to-end vaccine delivery solution, will allow for the distribution of approximately 50,000 doses of the Pfizer-BioNTech COVID-19 Vaccine in Ghana, pioneering a new model for vaccine distribution…

 

Sanofi Pasteur
Press Releases – No new digest announcements identified

 

Serum Institute of India
NEWS & ANNOUNCEMENTS – No new digest announcements identified

 

Sinopharm/WIBPBIBP
News – No new digest announcements identified

 

Sinovac
Press Releases
SINOVAC COVID-19 Vaccine Authorized for Commercial Sale in Myanmar
2021/11/08

 

Vector State Research Centre of Viralogy and Biotechnology
Home – No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

 

::::::

GSK
Press releases for media
12 November 2021 Primary endpoint met in COMET-TAIL Phase III trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19

 

Merck
News releases
Merck and Ridgeback Announce Japanese Government to Purchase 1.6 Million Courses of Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, Upon Authorization or Approval
11/10/2021

Merck and Ridgeback Announce U.S. Government to Purchase 1.4 Million Additional Courses of Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults
11/9/2021

 

Novartis
News – No new digest announcements identified

 

SK Biosciences
Press releases
SK bioscience Announces Positive Data from Phase I/II Clinical Trial of COVID-19 Vaccine Candidate
2021. 11. 05

 

Valneva
Press Releases
Valneva Announces European Commission Approval of Advance Purchase Agreement for up to 60 Million Doses of Inactivated COVID-19 Vaccine VLA2001
November 10, 2021